Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Launched by FEDERICO MARTINÓN TORRES · Dec 21, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a new treatment called nirsevimab for preventing respiratory syncytial virus (RSV) infections in children. RSV is a common virus that can cause serious respiratory illnesses, especially in young children. The trial will use health data from children in Galicia, Spain, to see how well nirsevimab works when given as a routine vaccination. The researchers hope to gather information from about 14,000 eligible children during each RSV season.
To be part of this study, children need to be born in Galicia between April 1, 2023, and March 1, 2026. There are no special exclusion criteria mentioned, which means most babies born during this time can participate. Families participating in the trial can expect to provide information about their child's health and any healthcare visits related to RSV. This information will help researchers understand how effective nirsevimab is in protecting children from RSV.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects born in Galicia from April 1st, 2023 and March 1st, 2026
- Exclusion Criteria:
- • No specific criteria has been reported
About Federico Martinón Torres
Federico Martinón Torres is a distinguished clinical trial sponsor renowned for his expertise in pediatric infectious diseases and vaccine research. With a robust background in clinical medicine and extensive experience in leading innovative studies, he is committed to advancing public health through rigorous scientific investigation. His collaborative approach fosters partnerships across academic, governmental, and pharmaceutical sectors, ensuring the development of safe and effective therapeutic interventions for children. Under his guidance, clinical trials are conducted with the highest ethical standards, aiming to enhance healthcare outcomes and contribute to the global understanding of infectious diseases in pediatric populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago De Compostela, , Spain
Santiago De Compostela, A Coruña, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported